{
    "nctId": "NCT04198727",
    "briefTitle": "Study of the Impact of DPD Activity on the Efficacy of Capecitabine",
    "officialTitle": "Study of the Impact of DPD Activity on the Efficacy of Capecitabine",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasm Malignant Female",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 155,
    "primaryOutcomeMeasure": "6 months objective response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age over 18,\n* Performance status 0 to 2,\n* Patients with metastatic HER2 negative breast cancer,\n* Patients eligible for capecitabine monotherapy at a dose of 2000 mg / m\u00b2 / day, 14 days every 21 days,\n* Determination of Uracil level performed according to national recommendations,\n* Patients with at least one lesion evaluable according to the RECIST criteria 1.1, or presenting at least 1 hypermetabolic lesion on PET-TDM according to PERCIST 1.0 criteria. In the case of single cutaneous metastasis (s), it is required to make photographs of lesions with a measure of the lesions using a ruler,\n* Patients receiving social coverage.\n\nExclusion Criteria:\n\n* Performance status\\> 2,\n* Contraindication to capecitabine monotherapy at a dose of 2000 mg / m\u00b2 / day, 14 days every 21 days,\n* Presence of untreated or uncontrolled symptomatic cerebral or leptomeningeal metastases (unstable corticosteroid requirements) and / or non-clinically stable in the 3 months prior to inclusion,\n* History of cancer, with the exception of cancers in complete remission for more than 5 years, totally resected cutaneous basal cell carcinoma, in situ carcinoma or in situ cervical epithelioma treated,\n* Vulnerable people",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}